Jeffrey Finer, MD, PhD
Jeffrey Finer, MD, PhD, is the Chief Executive Officer and Co-Founder at Septerna. Dr. Finer has more than 35 years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several first-in-class drugs into clinical trials, developing novel technology platforms that integrate science and engineering, and new company creation.
As a Venture Partner at Third Rock Ventures, Dr. Finer was involved in the founding and launching of multiple biotech companies, including Maze Therapeutics and Ambys Medicines, and served as interim Chief Technology Officer at both. Previously, Dr. Finer spent several years in research and development leadership positions, including Vice President, Research Technology at Theravance Biopharma, Vice President, Discovery at Five Prime Therapeutics, and Director, Drug Discovery Technologies at Cytokinetics.
Dr. Finer obtained his MD and PhD in Biochemistry from Stanford University School of Medicine, and he holds BS degrees in Chemistry and Biology from the Massachusetts Institute of Technology. He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School.